Oncolytics Logo
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

News Releases

  • News Releases
Latest News Release
Nov 24, 2000

Corporate Update

Nov 23, 2000

Announces Filing Of Its Initial Annual Information Form And Eligibility Under The Prompt Offering Qualification System

Nov 20, 2000

Provides Taped Conference Call Regarding Today’s Announcement For Licensing Agreement For Veterinary Use

Nov 20, 2000

Enters Agreement With Pfizer Inc.

Nov 17, 2000

Reports Third Quarter Results

Nov 10, 2000

Announces Results Of Reolysis® Treatment Of Brain Tumors In nimal Models

Oct 24, 2000

Receives Second U.S. Patent Approval

Oct 16, 2000

Presents Canine Pilot Study Results At The Veterinary Cancer Society Conference

  • 1
  • 2
  • 3
  • 4

Year
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • News
Dec 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles
Aug 9, 2016

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

@Oncolytics May 16, 2022

Due to unexpected COVID-19 issues, Oncolytics will not be able to participate in the RBC Conference on Wednesday. W… https://t.co/qnLGkbf6Wp

@Oncolytics May 10, 2022

CEO Matt Coffey will be at the 2022 @RBC Capital Markets Global Healthcare Conference participating in a fireside c… https://t.co/8fVv0S6Gbk

Follow us on Twitter
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

Sign up to receive email updates

Sign Up
Linkedin Icon
  • Privacy | Legal Notice
Copyright © Oncolytics Biotech® Inc. 2022 All rights reserved

Site by
Site by Pace Creative Alberta Site by Pace Creative Alberta